Related content

Enzyme replacement therapy in Fabry disease

By Brady R.   Murray G.   Moore D.   Schiffmann R.  

Journal of Inherited Metabolic Disease, Vol. 24, Iss. 2, 2001-04 ,pp. : 18-24

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide

By Whitfield P.   Calvin J.   Hogg S.   O’Driscoll E.   Halsall D.   Burling K.   Maguire G.   Wright N.   Cox T.   Meikle P.   Deegan P.  

Journal of Inherited Metabolic Disease, Vol. 28, Iss. 1, 2005-01 ,pp. : 21-33

Springer Publishing Company

Access to resources Recommend Favorite

CNS involvement in Fabry disease: Clinical and imaging studies before and after 12 months of enzyme replacement therapy

By Jardim L.   Vedolin L.   Schwartz I. V. D.   Burin M. G.   Cecchin C.   Kalakun L.   Matte U.   Aesse F.   Pitta-Pinheiro C.   Marconato J.   Giugliani R.  

Journal of Inherited Metabolic Disease, Vol. 27, Iss. 2, 2004-01 ,pp. : 229-240

Springer Publishing Company

Access to resources Recommend Favorite

Clinical benefit in Fabry patients given enzyme replacement therapy—A case series

By Guffon N.   Fouilhoux A.  

Journal of Inherited Metabolic Disease, Vol. 27, Iss. 2, 2004-01 ,pp. : 221-227

Springer Publishing Company

Access to resources Recommend Favorite

Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease

By Dehout F.   Roland D.   de Granseigne S.   Guillaume B.   Van Maldergem L.  

Journal of Inherited Metabolic Disease, Vol. 27, Iss. 4, 2004-07 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite